Last week also at Myology 2019 conference Roche shared early observations from Sunfish Part I clinical trial of risdiplam.
We are excited to share early observations from Firefish Part I clinical trial of risdiplam. The data were shared with researchers at the Myology Congress in Bordeaux last week.
Another country is joininig the group of those that treat spinal musculatr atrophy as the health authorities in Argentina have decided to provide nusinersen (Spinraza) under national healthcare.
A person with SMA impacts the NHS on average £49,723 annually in direct costs, while a loss of productivity per unpaid caregiver costs the society £14,350 each year.